Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

P53LAZARUS

Financiado

Cerrado

Tumour suppressor p53 structure stability and novel anti cancer drug developme...

Tumour suppressor p53 structure stability and novel anti cancer drug development Elimination of the tumour suppression activities of p53 is common to all cancers. p53 is inactivated directly by mutation in ~50% of human cancers, and ~30-40% of these oncogenic mutants are just temperature sensitive, ts, being a... ver más

31/07/2017

NC3Rs

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

National Centre for the Replacement Refinemen... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NC3Rs

0.00€ | Lider

Proyectos interesantes

TRANSREAD

Medical Technol...

Applied Physics

2M€ Cerrado

ResistSOS

Medical Technol...

Applied Physics

3M€ Cerrado

MYCinTOPshape

Medical Technol...

Applied Physics

2M€ Cerrado

P73CANCER

Medical Technol...

Applied Physics

1M€ Cerrado

SENESCENCE THERAPY

Medical Technol...

Applied Physics

100K€ Cerrado

Oncoswitch

Medical Technol...

Data Science

209K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

National Centre for the Replacement Refinemen... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Elimination of the tumour suppression activities of p53 is common to all cancers. p53 is inactivated directly by mutation in ~50% of human cancers, and ~30-40% of these oncogenic mutants are just temperature sensitive, ts, being active at lower temperatures. Wild-type p53 spontaneously denatures, with a half-life of 10-20 minutes at body temperature, and ts mutants far faster. The melting temperature and half life of ts oncogenic mutants can be raised by small molecules. The mutant Y220C is particularly propitious for study and as a target for therapy as the mutation makes a druggable cavity. We discovered lead compounds for a novel class of anti-cancer drugs that could be used to treat 70-80,000 new cases of cancer per annum worldwide via reactivating Y220C. I present a programme to understand the basic principles of stabilising Y220C in particular and the thermodynamics and kinetics of ts mutant proteins in general. Such studies may aid the development of lead compounds for reactivating Y220C into prospective drugs and will act as a paradigm for development of the ¿holy grail¿ of a generic p53-reactivating drug. This is not a classical drug screening programme but a fundamental study on how to stabilise proteins whose poor stability causes disease, and which pulls together the twin interests of the applicant in fundamental protein folding and the structural biology of p53. I will investigate the biophysical and structural characteristics of how to stabilize proteins by small molecules using the leads thrown up by the drug-screening programme. Even if none of the leads make it to the clinic, they will be important substrates for the structure-activity studies on the mechanisms of protein stabilization, which will be of general importance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores